Treatment innovations for pancreatic adenocarcinoma Jan. 27, 2020 Overview Mostrar la transcripción Overview Historically, most patients with pancreatic cancer whose tumors grow outside the pancreas to encompass veins and arteries have been told that the cancer is inoperable and they should prepare for an average survival time of 12 to 18 months. Mayo Clinic surgical oncologists Mark J. Truty, M.D., M.S., and Chee-Chee H. Stucky, M.D., share the latest treatment innovations for pancreatic adenocarcinoma and explain how these innovations have extended survival. VID-20479495 Profesionales médicos Treatment innovations for pancreatic adenocarcinoma